About cullinan therapeutics inc - CGEM
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM At a Glance
Cullinan Therapeutics, Inc.
One Main Street
Cambridge, Massachusetts 02142
| Phone | 1-617-410-4650 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -219,879,000.00 | |
| Sector | Health Technology | Employees | 109 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CGEM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.526 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.978 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.011 |
CGEM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,017,238.532 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CGEM Liquidity
| Current Ratio | 10.248 |
| Quick Ratio | 10.248 |
| Cash Ratio | 10.013 |
CGEM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -41.039 |
| Return on Equity | -44.017 |
| Return on Total Capital | -53.445 |
| Return on Invested Capital | -43.896 |
CGEM Capital Structure
| Total Debt to Total Equity | 0.656 |
| Total Debt to Total Capital | 0.652 |
| Total Debt to Total Assets | 0.597 |
| Long-Term Debt to Equity | 0.466 |
| Long-Term Debt to Total Capital | 0.463 |